Experiment 1027222
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Empty organism |
| Citation | SCARFFE,JH: BEAUMONT,AR: CROWTHER,D:. (1983). PHASE I-II EVALUATION OF ACRONINE IN PATIENTS WITH MULTIPLE MYELOMA.. 67(1) |
| Amount utilized | |
| Compound isolated | |
| Disease | A PHASE I-II STUDY INVOLVING 16 PATIENTS WITH MULTIPLE MYELOMA,RESISTANT TO CONVENTIONAL TREATMENT. DAILY DOSING AT 200 MG/SQ M FOR THE FIRST MONTH,THEREAFTER INCREASING MONTHLY BY 100 MG/SQ M/DAY,TO A MAXIMUM TOLERATED DOSE OF 500 MG/SQ M/DAY. ALL PATIENTS COMPLAINED OF ANOREXIA INITALLY,NAUSEA+VOMITING WAS DOSE LIMITING IN 1/2 OF THE PATIENTS. 7 OF THE 11 PATIENTS WHO RECEIVED A DAILY DOSE MORE THAN 300 MG/SQ M HAD EPISODES OF NAUSEA AND VOMITING. TREATMENT WAS STOPPED IN 1 PATIENT BECAUSE OF INTOLERABLE VOMITING. A RISE IN LIVER ENZYME LEVELS WAS NOTED IN ONE PATIENT WHO RECEIVED 300 MG/SQ M DAILY FOR 14 WEEKS. MILD MYELOSUPRESSION WAS OBSERVED IN TWO PATIENTS,BUT THE BOTH HAD RAPIDLY ADVANCING DISEASE WITH INCREASING BONE MARROW INFILTRATION. ONE PATIENT WHO RECEIVED 300 MG/SQ M FOR A TOTAL OF 93 WEEKS UP TO A MAXIMUM DAILY DOSE OF 400 MG/SQ M DEVELOPED SEVERE ATAXIA. THE ATAXIA GRADUALLY DISAPPEARED OVER A PERIOD OF 8 WEEKS AFTER TREATMENT WAS STOPPED. OBJECTIVE RESPONSE WAS SEEN IN ONLY ONE OF 16 PATIENTS TREATED WITH THE TITLE DRUG. THIS WAS THE SAME PATIENT WHO RECEIVED THE DRUG FOR 93 WEEKS BEFORE THE DRUG WAS STOPPED BECAUSE OF THE DEVELOPMENT OF ATAXIA. THE CONCLUSION OF THE STUDY WAS THAT ACRONYCINE SHOWED MINIMAL ACTIVITY,BUT THE DOSE USED WAS CLEARLY LIMITED BY NAUSEA AND VOMITING. IF A MORE TOLERABLE FORMULATION OF THE DRUG BECAME AVAILABLE,FURTHER STUDIES WOULD BE INDICATED AT HIGHER DOSES. |
| Dose amount | 200.0 MG |
| Number | 1 |
| Qualitative result | EQUIVOCAL |
| Animal | HUMAN ADULT |
| Per unit | SQ M BODY SURFACE |
| Dose expression | DOSE |